Zydus Lifesciences Limited has received favorable news regarding a GST penalty case involving its subsidiary. The pharmaceutical company announced that German Remedies Pharmaceuticals Private Limited (GRPPL), a wholly owned subsidiary, has successfully overturned a penalty order through an appeal process.

GST Penalty Appeal Success

GRPPL had previously received a Demand Order-In-Original imposing a penalty of Rs. 1.66 million for the financial year 2018-19. The penalty was related to alleged excess availment of Input Tax Credit under the Central GST Act. The company had filed an appeal against this order before the Office of Commissioner, Central GST, Appeal Ahmedabad Commissionerate.

Appeal Order Details

The appellate authority has issued an order confirming that the penalty amount under section 74 of the CGST Act, 2017, of Rs. 1.66 million has been completely dropped. The Appeal Order was dated April 1, 2026, and was received by the authorized officials of the company on April 15, 2026, at 10.58 a.m.

Financial Impact Assessment

Zydus Lifesciences has evaluated the impact of this favorable decision and concluded that there is no material impact on the financials, operations, or other activities of either GRPPL or the parent company. The successful appeal represents a positive outcome for the pharmaceutical group, eliminating a potential financial liability.

Corporate Structure Context

German Remedies Pharmaceuticals Private Limited operates as a wholly owned subsidiary of Zydus Healthcare Limited, which is itself a wholly owned subsidiary of Zydus Lifesciences Limited. This multi-tiered structure is common in pharmaceutical companies to manage different business segments and regulatory requirements across various markets and product categories.

Zydus Lifesciences Limited has received an improved ESG (Environmental, Social, and Governance) rating from a SEBI-registered rating provider, marking a positive development in the company's sustainability assessment. The pharmaceutical company disclosed this information to stock exchanges as part of its regulatory compliance obligations.

ESG Rating Details

ESG Risk Assessments and Insights Limited (ESGRAIL), a SEBI-registered ESG rating provider, has assigned an overall ESG rating to the company. The rating assessment shows year-over-year improvement in the company's ESG performance.

Independent Assessment Process

The company emphasized that it had not engaged ESGRAIL for the ESG rating assessment. ESGRAIL independently prepared the report based on publicly available information, demonstrating the provider's autonomous evaluation methodology. This independent approach ensures objectivity in the rating process without any direct company influence.

Regulatory Compliance

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III. The company also referenced SEBI circulars dated November 11, 2024, and December 31, 2024, as part of its regulatory framework for ESG disclosures.

Company Secretary and Compliance Officer Dhaval N. Soni signed the disclosure document on April 10, 2026, ensuring proper corporate governance procedures were followed. The disclosure was simultaneously submitted to both BSE Limited and National Stock Exchange of India Limited, maintaining transparency across all trading platforms.